Sample Page
Author:
BriaCell Therapeutics Corp.
Posted Date:
April 21, 2026
BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models
BriaCell Therapeutics Corp.
April 21, 2026
BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting
BriaCell Therapeutics Corp.
April 20, 2026
BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License
BriaCell Therapeutics Corp.
March 31, 2026
BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference
BriaCell Therapeutics Corp.
March 18, 2026
BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting
BriaCell Therapeutics Corp.
March 10, 2026
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
BriaCell Therapeutics Corp.
March 5, 2026
BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License
BriaCell Therapeutics Corp.
February 18, 2026
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
BriaCell Therapeutics Corp.
February 17, 2026
BriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune Activation
BriaCell Therapeutics Corp.
January 28, 2026
BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients
BriaCell Therapeutics Corp.
January 28, 2026
